Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
23.23
+1.10 (4.97%)
At close: Apr 2, 2026, 4:00 PM EDT
22.95
-0.28 (-1.21%)
After-hours: Apr 2, 2026, 7:56 PM EDT
Sarepta Therapeutics Revenue
In the year 2025, Sarepta Therapeutics had annual revenue of $2.20B with 15.58% growth. Sarepta Therapeutics had revenue of $442.93M in the quarter ending December 31, 2025, a decrease of -32.73%.
Revenue (ttm)
$2.20B
Revenue Growth
+15.58%
P/S Ratio
1.11
Revenue / Employee
$2,632,619
Employees
835
Market Cap
2.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.20B | 296.26M | 15.58% |
| Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
| Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
| Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
| Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
| Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
| Dec 31, 2019 | 380.83M | 79.80M | 26.51% |
| Dec 31, 2018 | 301.03M | 146.45M | 94.74% |
| Dec 31, 2017 | 154.58M | 149.16M | 2,751.58% |
| Dec 31, 2016 | 5.42M | 4.17M | 332.64% |
| Dec 31, 2015 | 1.25M | -8.50M | -87.16% |
| Dec 31, 2014 | 9.76M | -4.46M | -31.38% |
| Dec 31, 2013 | 14.22M | -23.11M | -61.91% |
| Dec 31, 2012 | 37.33M | -9.66M | -20.56% |
| Dec 31, 2011 | 46.99M | 17.57M | 59.72% |
| Dec 31, 2010 | 29.42M | 11.84M | 67.30% |
| Dec 31, 2009 | 17.59M | -3.67M | -17.28% |
| Dec 31, 2008 | 21.26M | 10.27M | 93.52% |
| Dec 31, 2007 | 10.99M | 10.87M | 9,428.06% |
| Dec 31, 2006 | 115.29K | -4.67M | -97.59% |
| Dec 31, 2005 | 4.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zai Lab | 460.16M |
| Adaptive Biotechnologies | 276.98M |
| Day One Biopharmaceuticals | 158.18M |
| Beam Therapeutics | 139.74M |
| Ascentage Pharma Group International | 82.08M |
| Nektar Therapeutics | 55.23M |
SRPT News
- 3 days ago - Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 9 days ago - Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 Transcript - Seeking Alpha
- 10 days ago - Why Is Sarepta Therapeutics Stock Exploding Today? - Benzinga
- 10 days ago - Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Business Wire
- 10 days ago - Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - Business Wire
- 16 days ago - Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs - Benzinga
- 16 days ago - Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53® - Business Wire
- 19 days ago - Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne - Business Wire